Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Tiziana Life Sciences Plc (TILS.LN)

Tiziana Life Sciences Plc (TILS.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 113,848
  • Shares Outstanding, K 194,612
  • Annual Sales, $ 0 K
  • Annual Income, $ -17,691 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.23
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.17
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
45.000 +30.00%
on 10/20/21
59.000 -0.85%
on 10/20/21
+4.000 (+7.34%)
since 09/20/21
3-Month
45.000 +30.00%
on 10/20/21
77.000 -24.03%
on 09/03/21
-5.000 (-7.87%)
since 07/20/21
52-Week
30.000 +95.00%
on 05/20/21
195.000 -70.00%
on 01/20/21
-112.500 (-65.79%)
since 10/20/20

Most Recent Stories

More News
Tiziana Life Sciences Appoints Matthew W. Davis, MD, RPh as Chief Medical Officer and Acting Chief Scientific Officer

NEW YORK, July 18, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling...

TILS.LN : 58.500 (+8.33%)
TLSA : 1.0300 (+15.67%)
Tiziana Life Sciences Announces Resignation of CEO

NEW YORK, July 15, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling...

TILS.LN : 58.500 (+8.33%)
TLSA : 1.0300 (+15.67%)
Tiziana Life Sciences Ltd. Receives Nasdaq Deficiency Notice

NEW YORK, June 17, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling...

TLSA : 1.0300 (+15.67%)
TILS.LN : 58.500 (+8.33%)
Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman

NEW YORK, June 10, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling...

TILS.LN : 58.500 (+8.33%)
TLSA : 1.0300 (+15.67%)
Tiziana Life Sciences PLC (TLSA: NASDAQ) Releases Research Report: Clinical Improvements for 2nd SPMS Patient

Zacks Small-Cap Research Note By John D. Vandermosten, CFA NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences PLC (NASDAQ: TLSA)...

TILS.LN : 58.500 (+8.33%)
TLSA : 1.0300 (+15.67%)
Tiziana Life Sciences Announces An Interview on Clinical Improvements for 2nd SPMS Patient

NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling...

TILS.LN : 58.500 (+8.33%)
TLSA : 1.0300 (+15.67%)
Tiziana Life Sciences PLC (TLSA: NASDAQ) Clinical Improvements for 2nd SPMS Patient

Research Note Clinical Results for Second SPMS Patient NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences PLC (NASDAQ: TLSA)...

TILS.LN : 58.500 (+8.33%)
TLSA : 1.0300 (+15.67%)
Tiziana Life Sciences to Present at the 2022 Biotechnology Innovation Organization Annual Convention to Discuss Recent Updates to Ongoing Clinical Programs

NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (NASDAQ: TLSA) ("Tiziana" or the "Company"), a clinical-stage biopharmaceutical...

TILS.LN : 58.500 (+8.33%)
TLSA : 1.0300 (+15.67%)
Tiziana Life Sciences Ltd. Announces Annual Report Filed to Regain Nasdaq Compliance

Form 20-F Filed on May 23, 2022 Following Receipt of Notice from Nasdaq Regarding Filing Deadline of its Annual Report...

TLSA : 1.0300 (+15.67%)
TILS.LN : 58.500 (+8.33%)
Tiziana Life Sciences to participate in a Fireside Chat At the B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference

NEW YORK, April 26, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (NASDAQ: TLSA) ("Tiziana" or the "Company"), a clinical-stage biopharmaceutical...

TILS.LN : 58.500 (+8.33%)
TLSA : 1.0300 (+15.67%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

3rd Resistance Point 77.333
2nd Resistance Point 68.167
1st Resistance Point 63.333
Last Price 58.500
1st Support Level 49.333
2nd Support Level 40.167
3rd Support Level 35.333

See More

52-Week High 195.000
Fibonacci 61.8% 131.970
Fibonacci 50% 112.500
Fibonacci 38.2% 93.030
Last Price 58.500
52-Week Low 30.000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar